TransmedicsTMDX
TMDX
About: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Employees: 584
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
73% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 44
60% more call options, than puts
Call options by funds: $82.4M | Put options by funds: $51.6M
10% more funds holding
Funds holding: 332 [Q2] → 364 (+32) [Q3]
8% more capital invested
Capital invested by funds: $5.21B [Q2] → $5.65B (+$436M) [Q3]
3.1% more ownership
Funds ownership: 105.12% [Q2] → 108.22% (+3.1%) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 121
36% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 9 (-5) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$75
22%
upside
Avg. target
$106
72%
upside
High target
$125
103%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
JP Morgan Allen Gong 44% 1-year accuracy 4 / 9 met price target | 22%upside $75 | Neutral Downgraded | 17 Dec 2024 |
Piper Sandler Matt O'Brien 57% 1-year accuracy 29 / 51 met price target | 46%upside $90 | Overweight Maintained | 11 Dec 2024 |
Baird Joe Vruwink 50% 1-year accuracy 21 / 42 met price target | 94%upside $120 | Outperform Maintained | 11 Dec 2024 |
Oppenheimer Suraj Kalia 36% 1-year accuracy 8 / 22 met price target | 103%upside $125 | Outperform Maintained | 3 Dec 2024 |
Canaccord Genuity William Plovanic 57% 1-year accuracy 26 / 46 met price target | 69%upside $104 | Buy Maintained | 20 Nov 2024 |
Financial journalist opinion
Based on 15 articles about TMDX published over the past 30 days
Negative
Zacks Investment Research
1 week ago
TransMedics Stock Plunges 57.5% in Three Months: What's Next?
TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance.
Neutral
PRNewsWire
1 week ago
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , Dec. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 9, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 20,612 shares of its common stock and an aggregate of 13,576 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment with TransMedics.
Neutral
The Motley Fool
1 week ago
Is TransMedics Stock a Buy Before 2025?
In today's video, I will discuss recent updates about TransMedics (TMDX -2.36%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Positive
The Motley Fool
1 week ago
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
I've long viewed healthcare as one of the best sectors for long-term investors because everybody requires healthcare products and services sooner or later. With aging populations in the U.S. and other major countries, the demand will almost certainly increase over the next decade and beyond.
Positive
The Motley Fool
1 week ago
Down Over 60%, Is TransMedics Stock a Buy on the Dip?
TransMedics Group (TMDX 3.03%) was a top-performing stock that more than doubled in value during the months between the end of 2023 and late August.
Negative
The Motley Fool
2 weeks ago
Why Transmedics Group Stock Plummeted 21% This Week
Shares of Transmedics Group (TMDX 2.13%) sank over 20% this week, according to data from S&P Global Market Intelligence. The organ transplant disrupter announced a CFO transition and reduced the range for its full-year 2024 guidance, indicating slowing revenue growth.
Neutral
Seeking Alpha
2 weeks ago
TransMedics: A Look At What Is Behind The Loss Of Sales Momentum In H2 2024
TransMedics shares declined 60% from their August peak after a Q3 revenue miss, and more recently by slightly reduced revenue guidance range, surprising investors accustomed to beat-and-raise guidance. The company faces near-term challenges, but long-term growth prospects remain strong. The CEO suggested a temporary pause in growth at the Piper Sandler conference this week, with stronger performance expected in 2H 2025, driven by clinical data from heart and lung programs.
Neutral
PRNewsWire
2 weeks ago
TMDX INVESTIGATION: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the TransMedics investigation or if you are a TransMedics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-transmedics-group-inc-investigation-tmdx.html You can also contact attorneys J.C.
Neutral
The Motley Fool
2 weeks ago
Why TransMedics Stock Plummeted Today
Shares of leading organ transplant platform TransMedics (TMDX -15.43%) were down 14% as of noon ET on Wednesday, according to data provided by S&P Global Market Intelligence.
Negative
Benzinga
2 weeks ago
Zscaler, TransMedics Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday.
Charts implemented using Lightweight Charts™